Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Intensity Therapeutics 與瑞士臨床癌症研究集團簽署合作協議 SAKK 將在歐洲進行 INT230-6 的二期乳腺癌試驗
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Intensity Therapeutics 與瑞士臨床癌症研究集團簽署合作協議 SAKK 將在歐洲進行 INT230-6 的二期乳腺癌試驗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。